Is a malaria vaccine a wise investment for countries and international partners?
Countries with malaria face a wide range of challenges. One significant challenge is constructing the optimal menu of interventions to deal with their critical public health problems. MVI is undertaking a comprehensive scope of economic analyses at the country level, interlinked with more globally oriented Return on Investment analyses. We are working with Johns Hopkins University as well as economists and social scientists in seven African countries to conduct comprehensive economic analyses to inform use of malaria vaccines. The analyses build on other economic work, including that related to intermittent presumptive treatment in infants (IPTI). (Read more on the website of the IPTI Consortium.) Through our economic work, we will ensure that countries have robust, credible country-level data to answer the following questions: • Is the vaccine cost effective? • Does it make sense for us to include this vaccine in our Expanded Program on Immunization (EPI) schedule, given the evidence
